American Shared Hospital Services (AMS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture with both positive and negative aspects. While there is growth in certain areas like the Puebla facility and Gamma Knife revenue, overall revenue and gross margins have declined year-over-year. The Q&A section reveals concerns about market valuation and management's vague responses. Despite some improvements in specific metrics, the lack of clear guidance and the company's thin trading volume suggest a neutral market reaction. Without a clear strategy to address these issues, the stock price is likely to remain stable in the short term.
Key Financial Performance
Third Quarter Revenue $7.2 million, a 2.5% increase year-over-year, driven by increased procedures at the new facility in Puebla, Mexico.
Direct Patient Services Revenue $4 million, a 9.4% increase year-over-year, primarily due to increased procedures at the Puebla, Mexico facility.
Medical Equipment Leasing Revenue $3.1 million, a decrease from $3.3 million year-over-year, due to lower proton beam radiation therapy volumes.
Gamma Knife Revenue $2.1 million, a 16% increase year-over-year, with procedures increasing from 218 to 231.
Proton Beam Radiation Therapy Revenue $2.1 million, a 10.8% increase from Q2 2025, but an 8.1% decrease in therapy fractions year-over-year due to cyclical fluctuations.
Linear Accelerator (LINAC) Systems Revenue $2.9 million, a 15.9% increase from Q2 2025 and a 51.2% increase year-over-year, driven by operations in Puebla, Mexico and Rhode Island.
Gross Margins 22.1%, a 16% year-over-year increase to $1.6 million, primarily due to higher treatment volumes.
Operating Income Loss of $344,000, an improvement from a loss of $889,000 year-over-year.
Net Loss $55,000, an improvement from a net loss of $207,000 year-over-year.
Adjusted EBITDA $1.9 million, a 41% increase year-over-year from $1.4 million.
Year-to-Date Revenue $20.4 million, a 5.6% increase year-over-year, driven by Rhode Island and Puebla, Mexico operations.
Direct Patient Care Services Revenue (Year-to-Date) $10.7 million, a 36.5% increase year-over-year, driven by Rhode Island and Puebla, Mexico operations.
Equipment Leasing Revenue (Year-to-Date) $9.7 million, a decrease from $11.5 million year-over-year, due to expired contracts and lower PBRT volumes.
Gamma Knife Revenue (Year-to-Date) $6.8 million, a 4.2% decrease year-over-year, due to expired contracts and lower PBRT volumes.
Proton Beam Radiation Therapy Revenue (Year-to-Date) $5.7 million, a 23% decrease year-over-year, due to cyclical fluctuations.
Linear Accelerator (LINAC) Systems Revenue (Year-to-Date) $9.7 million, a significant increase from $4.8 million year-over-year, driven by Rhode Island and Puebla, Mexico operations.
Gross Margin (Year-to-Date) $4.2 million, a 20.4% decrease year-over-year, reflecting lower volumes and increased operating costs.
Operating Loss (Year-to-Date) $2.2 million, compared to a loss of $975,000 year-over-year.
Net Loss (Year-to-Date) $922,000, compared to net income of $3.5 million year-over-year, primarily due to a $3.9 million bargain purchase gain in 2024.
Adjusted EBITDA (Year-to-Date) $4.6 million, compared to $5.1 million year-over-year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Radiation Therapy Treatment Center in Puebla, Mexico: Achieved 263% annual revenue growth, showcasing significant growth potential.
Gamma Knife Revenue: Increased by almost 17% year-over-year, indicating strong performance in this segment.
Expansion in Rhode Island: Acquired three cancer treatment centers and planning to construct two new facilities, including the first proton beam radiation therapy center in the state.
International Expansion: Opened a new center in Puebla, Mexico, and planning to open a Gamma Knife center in Guadalajara, Mexico, by Q2 2026.
Transition to Direct Patient Care Services: Revenue from direct patient care services now constitutes 56% of total revenue, reflecting a strategic shift from equipment leasing.
Operational Efficiencies: Gross margins increased by 16%, and operating loss improved by 92% year-over-year.
Growth Strategy: Focused on long-term shareholder value through revenue growth, operational efficiencies, and strategic expansions.
Business Development Initiatives: Emphasizing physician engagement and partnerships to drive treatment volumes and market share.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue from equipment leasing segment: Decreased to $9.7 million from $11.5 million in the first 9 months of 2024, primarily due to the expiration of 3 customer contracts since Q4 2024 and lower proton beam radiation therapy (PBRT) volumes.
Gamma Knife revenue: Declined 4.2% to $6.8 million for the first 9 months of 2025 compared to $7.1 million in the first 9 months of 2024, with the number of procedures dropping from 831 to 703 due to contract expirations and lower volumes.
Proton beam radiation therapy (PBRT) revenue: Decreased 23% to $5.7 million in the first 9 months of 2025 compared to $7.4 million in the first 9 months of 2024, with therapy fractions declining 18% due to cyclical fluctuations.
Gross margin: Declined to $4.2 million for the first 9 months of 2025 compared to $6 million in the same period of 2024, reflecting lower volumes and increased operating costs from the shift to direct patient services.
Net loss: Increased to $922,000 for the first 9 months of 2025 compared to net income of $3.5 million in the same period of 2024, primarily due to the absence of a $3.9 million bargain purchase gain from the Rhode Island acquisition in 2024.
Cash and cash equivalents: Declined to $5.3 million as of September 30, 2025, from $11.3 million at December 31, 2024, due to $7.5 million spent on capital expenditures for new facilities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects continued growth in treatment volumes, particularly in Rhode Island, and anticipates additional growth in the fourth quarter of 2025. The new radiation therapy treatment center in Puebla, Mexico, showed a 263% annual revenue growth, and the company expects stronger international growth from additional treatment volumes in Ecuador, Peru, and Mexico.
New Facility Openings: The company plans to open a Gamma Knife center in Guadalajara, Mexico, in the second quarter of 2026, which will be the only Esprit Gamma Knife in Mexico. Additionally, the company is constructing a fourth radiation therapy center in Bristol, Rhode Island, and the first proton beam radiation therapy center in Rhode Island.
Market Expansion: The company is focused on expanding its footprint in Rhode Island and internationally, with growth opportunities in its existing and new centers in Mexico, Peru, and Ecuador.
Operational Efficiency: The company remains focused on improving profitability through operational efficiencies and expects steady growth in treatment volumes through physician engagement and partnerships with health system joint ventures.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why is the company's market valuation so low despite positive results and a strong pipeline?
A:Management acknowledged the low market valuation and attributed it to the company's debt and limited investor exposure. They agreed that more investor outreach and participation in conferences could help address this issue. They also emphasized their focus on operational efficiencies and cost management.
Q:What is management's opinion on the disconnect between the company's positive performance and its 52-week low trading price?
A:Management believes the disconnect is due to the company being thinly traded and having limited exposure. They agreed with the suggestion to increase outreach and noted that consistent positive results over several quarters are needed to gain market recognition. The Investor Relations firm also supported the idea of increasing exposure and highlighted the sequential improvement in the company's performance over the last three quarters.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to why the market is not acknowledging the company's positive performance and undervaluation. Their responses lacked specific strategies or timelines for addressing the issue, focusing instead on general comments about increasing exposure and operational focus.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CharterCARE equipment
Conference opening
Frech CFO
Island efficiency
Island permitting
Island progress
Puebla Mexico
afternoon term
area opening
benefit remainder
business fluctuation
care service
center Certificate
center Puebla
center patient
center radiation
center volume
closing plan
confidence year
continuation trend
course term
date result
date revenue
development confidence
efficiency benefit
efficiency improvement
efficiency profitability
element market
equipment patient
facility opportunity
fluctuation development
fluctuation medium
improvement efficiency
improvement treatment
increase patient
increase transition
patient care
place
term track
track record
transition equipment
AMS Transcript
American Shared Hospital Services (AMS) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call summary reveals moderate financial growth with a 4% revenue increase and improved operational efficiencies. However, the call lacks details on strategic initiatives and operational updates, and highlights significant risks such as regulatory changes, economic uncertainties, and supply chain disruptions. The absence of shareholder return discussions further tempers sentiment. Given these mixed factors, a neutral stock price movement is anticipated over the next two weeks.
American Shared Hospital Services (AMS) Q4 2025 Earnings Call Transcript
Unknown3-31
The earnings call reveals a mixed performance with declining leasing revenue and gross margins, alongside a net loss. Despite some growth in direct patient care services, the inability to provide guidance, especially on profitability, and the lack of a stock buyback program are concerning. The Q&A section highlights management's reluctance to offer forward-looking statements, contributing to uncertainty. Although there is strategic expansion, the financial health indicators suggest a negative sentiment, likely resulting in a stock price decrease of 2% to 8% over the next two weeks.
American Shared Hospital Services (AMS) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture with both positive and negative aspects. While there is growth in certain areas like the Puebla facility and Gamma Knife revenue, overall revenue and gross margins have declined year-over-year. The Q&A section reveals concerns about market valuation and management's vague responses. Despite some improvements in specific metrics, the lack of clear guidance and the company's thin trading volume suggest a neutral market reaction. Without a clear strategy to address these issues, the stock price is likely to remain stable in the short term.
American Shared Hospital Services (AMS) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals mixed signals: solid revenue growth and international expansion are offset by declining margins, increased expenses, and revenue drops in key areas. Although management shows optimism, the financials indicate challenges. Despite sequential improvements, year-over-year declines in key metrics and contract expirations raise concerns. The Q&A section highlights strategic staffing and partnerships, but these are not immediate catalysts. Without clear market cap data, a neutral rating is prudent, anticipating limited stock movement within -2% to 2% range due to offsetting positive and negative factors.
AMS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
